

Oncology Biosimilars Market Report by Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032

<https://marketpublishers.com/r/O1DDDF476F69EN.html>

Date: April 2024

Pages: 135

Price: US\$ 3,899.00 (Single User License)

ID: O1DDDF476F69EN

Abstracts

The global oncology biosimilars market size reached US\$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 30.3 Billion by 2032, exhibiting a growth rate (CAGR) of 22.3% during 2024-2032.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation

have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

- Monoclonal Antibody
- Immunomodulators
- G-CSF
- Hematopoietic Agents
- Others

Breakup by Cancer Type:

- Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Breast Cancer
- Kidney Cancer
- Stomach Cancer
- Brain Cancer
- Others

Breakup by Distribution Channel:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Breakup by Region:

Europe
Asia Pacific
North America
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:

How has the global oncology biosimilars market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global oncology biosimilars industry?

What are the key regional markets in the global oncology biosimilars industry?

What is the breakup of the market based on the drug type?

What is the breakup of the market based on the cancer type?

What is the breakup of the market based on the distribution channel?

What are the various stages in the value chain of the global oncology biosimilars industry?

What are the key driving factors and challenges in the global oncology biosimilars industry?

What is the structure of the global oncology biosimilars industry and who are the key players?

What is the degree of competition in the global oncology biosimilars industry?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL ONCOLOGY BIOSIMILARS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Drug Type
- 5.5 Market Breakup by Cancer Type
- 5.6 Market Breakup by Distribution Channel
- 5.7 Market Breakup by Region
- 5.8 Market Forecast

6 MARKET BREAKUP BY DRUG TYPE

- 6.1 Monoclonal Antibody
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast

6.2 Immunomodulators

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 G-CSF

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 Hematopoietic Agents

6.4.1 Market Trends

6.4.2 Market Forecast

6.5 Others

6.5.1 Market Trends

6.5.2 Market Forecast

7 MARKET BREAKUP BY CANCER TYPE

7.1 Lung Cancer

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Colorectal Cancer

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Cervical Cancer

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Breast Cancer

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Kidney Cancer

7.5.1 Market Trends

7.5.2 Market Forecast

7.6 Stomach Cancer

7.6.1 Market Trends

7.6.2 Market Forecast

7.7 Brain Cancer

7.7.1 Market Trends

7.7.2 Market Forecast

7.8 Others

7.8.1 Market Trends

7.8.2 Market Forecast

8 MARKET BREAKUP BY DISTRIBUTION CHANNEL

8.1 Hospital Pharmacies

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Online Pharmacies

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Retail Pharmacies

8.3.1 Market Trends

8.3.2 Market Forecast

8.4 Others

8.4.1 Market Trends

8.4.2 Market Forecast

9 MARKET BREAKUP BY REGION

9.1 Europe

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Asia Pacific

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 North America

9.3.1 Market Trends

9.3.2 Market Forecast

9.4 Middle East and Africa

9.4.1 Market Trends

9.4.2 Market Forecast

9.5 Latin America

9.5.1 Market Trends

9.5.2 Market Forecast

10 SWOT ANALYSIS

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Biocon Limited

14.3.2 Celltrion Inc.

14.3.3 Dr. Reddy's Laboratories Ltd.

14.3.4 Intas Pharmaceuticals Ltd.

14.3.5 STADA Arzneimittel AG

14.3.6 Pfizer Inc.

14.3.7 Apotex Inc.

14.3.8 Teva Pharmaceutical Industries Ltd.

14.3.9 Sandoz International GmbH

14.3.10 BIOCAD Biotechnology Company

14.3.11 Mylan N.V.

14.3.12 F. Hoffmann-La Roche AG

List Of Tables

LIST OF TABLES

Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US\$), 2024-2032

Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US\$), 2024-2032

Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US\$), 2024-2032

Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 6: Global: Oncology Biosimilars Market Structure

Table 7: Global: Oncology Biosimilars Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges

Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023

Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023

Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023

Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023

Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis

Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis

Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis

Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value

(in Million US\$), 2024-2032

Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US\$), 2018 & 2023

Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US\$), 2024-2032

Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US\$), 2018 & 2023

Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US\$), 2024-2032

Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US\$), 2018 & 2023

Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US\$), 2024-2032

Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US\$), 2018 & 2023

Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US\$), 2024-2032

Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US\$), 2018 & 2023

Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US\$), 2018 & 2023

Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US\$), 2018 & 2023

Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US\$), 2018 & 2023

Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US\$), 2018 & 2023

Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US\$), 2024-2032

I would like to order

Product name: Oncology Biosimilars Market Report by Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032

Product link: <https://marketpublishers.com/r/O1DDDF476F69EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O1DDDF476F69EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970